Transgene Stock

Transgene Current Liabilities

The Current Liabilities of Transgene (TNG.PA) as of Jul 24, 2026 is 13.98 M EUR. In the previous year, Current Liabilities was 10.04 M EUR — a change of 39.26% (higher).

Current Liabilities

13.98 MEUR

YoY

39.26%

Last updated:

Current Liabilities of Transgene is 2026 13.98 M EUR. Current Liabilities of Transgene was 2025 10.04 M EUR. It decreases by 39.26% higher compared to the previous year.
Access this data via the Eulerpool API

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Current Liabilities of Transgene is 13.98 M EUR in 2026.

Access this data via the Eulerpool API

Balance Sheet — Transgene

All Key Metrics — Transgene